The SalvaRx Group is a drug discovery and development company focused on immune-oncology; SalvaRx invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies. The SalvaRx Group was founded by Drs. Ian Walters and Rob Kramer, two former Bristol-Myers Squibb drug developers with a history of championing immune-oncology and developing immune-oncology therapeutics. SalvaRx has a mandate to assemble and develop a portfolio of differentiated immune-oncology therapies for the treatment of late-stage cancers. SalvaRx provides its portfolio companies with operational support in addition to capital, sometimes operating its portfolio companies directly and sometimes augmenting the current team.
In 2015, SalvaRx made its first investment in iOx Therapeutics, a University of Oxford spin-out that is developing a compounds that stimulate Natural Killer T Cells. SalvaRx Limited was acquired by 3Legs Resources in 2016, being readmitted to AIM in March 2016. SalvaRx made a further investment in Intensity Therapeutics in April 2016. In Spring 2017, SalvaRx made two additional investments, one a Series A investment into Rift Biotherapeutics, and another into a joint venture with Nekonal SARL to explore immuno-oncology applications of their technology. SalvaRx continues to review additional early stage opportunities in cancer immunotherapy
Ian B. Walters, M.D., M.B.A., is the Entrepreneur in Residence at Mediqventures and is part-time CMO of Intensity Therapeutics, Inc. Over his 20 year career, he has demonstrated both leadership and expertise in drug development, including the advancement of multiple cancer compounds from research stages through approval.
Ian specialises in the evaluation, prioritization, and the innovative development of new therapies for the treatment of severe diseases. He has worked at PDL BioPharma, Inc., Millenium Pharmaceuticals, Inc., and Sorrento Therapeutics, Inc., leading corporate development, translational medicine, clinical development and medical affairs.
Ian spent seven years at Bristol-Myers Squibb, where he managed physicians overseeing the international development of more than eight oncology compounds (including Nivolimab (anti-PD-1), Ipilimumab (anti-CTLA-4), brivanib (anti VEGF/FGF), anti-IGF/IR, VEGFR2 biologic, Elotuzimab (antiCS1), as well as biomarker and companion diagnostic work. He was a core member of Bristol- Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations, and the company’s immuno-oncology strategy.
Before entering the private sector, Ian was a lead investigator at the Rockefeller University and initiated advanced immunology research to understand the mechanism of action of several compounds. Ian received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.